Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Rodrigo Cid, Sanofi / AP
The FDA approved Regeneron Pharmaceuticals Inc. and Sanofi SA's new eczema drug Dupixent for sale today with the companies setting the list price at $37,000 annually, per the WSJ.
The companies made a point to negotiate with pharmacy-benefit managers and non-profit officials to set an acceptable price to ensure that patients can receive the drug with the fewest restrictions possible. Even still, CVS Health Corp. told the WSJ that the drug "will be expensive" for patients.
Still, the pricing is a genuine compromise that shows Regeneron and Sanofi put some thought into their decision given the political dynamics and negative headlines that have recently plagued high drug pricing.